7. Net Loss per Share

Basic net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding. Included in net loss is the deemed dividend from preferred shares issuance of $59,000 for the three months ended March 31, 2018. The deemed dividend relates to the discount provided to preferred stockholders upon conversion of their preferred stock to common shares and is subtracted from net loss (see Note 9). Diluted net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding including the effect of common share equivalents. Diluted net loss per share assumes the issuance of potentially dilutive common shares outstanding for the period and adjusts for any changes in income and the repurchase of common shares that would have occurred from the assumed issuance, unless such effect is anti-dilutive. The number of options and warrants for the purchase of common stock that were excluded from the computations of net loss per common share for the three months ended March 31, 2018 were 12,188,515 and 32,054,809, respectively, and for the three months and ended March 31, 2017 were 11,489,515 and 57,341,642, respectively.

The following tables set forth the computation of diluted net loss per weighted average number of shares outstanding attributable to Synthetic Biologics, Inc. and Subsidiaries for the three months ended March 31, 2018 and 2017 (in thousands except share and per share amounts):

	Three months ended March 31, 2018						Three months ended March 31, 2017
	Net loss (Numerator)		Shares (Denominator)		Per Share Amount		Net Loss (Numerator)		Shares (Denominator)		Per Share Amount
Net loss - Basic	$	(2,316)		128,566,883	$	(0.02)	$	(2,846)		117,447,260	$	(0.02)

Dilutive shares related to warrants		-		-		-		-		-		-

Net loss - Dilutive	$	(2,316)		128,566,883	$	(0.02)	$	(2,846)		117,447,260	$	(0.02)